TScan Therapeutics’ (TCRX) Outperform Rating Reaffirmed at Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 477.97% from the stock’s current price.

Several other analysts have also commented on TCRX. Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of TScan Therapeutics in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, TScan Therapeutics has an average rating of “Hold” and an average price target of $6.00.

TScan Therapeutics Trading Down 6.0%

Shares of TScan Therapeutics stock opened at $0.87 on Tuesday. The firm has a market cap of $56.53 million, a PE ratio of -0.90 and a beta of 1.03. TScan Therapeutics has a 1 year low of $0.85 and a 1 year high of $2.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The stock has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.06.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. Equities research analysts anticipate that TScan Therapeutics will post -1.11 EPS for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently modified their holdings of TCRX. Aberdeen Group plc boosted its holdings in TScan Therapeutics by 31.8% in the 4th quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock worth $1,785,000 after buying an additional 430,421 shares during the period. Renaissance Technologies LLC lifted its position in shares of TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after acquiring an additional 311,150 shares in the last quarter. Jane Street Group LLC lifted its position in shares of TScan Therapeutics by 377.5% during the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock worth $388,000 after acquiring an additional 306,968 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of TScan Therapeutics by 627.5% in the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock worth $339,000 after acquiring an additional 292,610 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of TScan Therapeutics by 1,142.5% in the fourth quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock worth $219,000 after acquiring an additional 201,375 shares during the period. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.